Equities analysts expect Aurora Cannabis Inc. (NYSE:ACB) to post $47.12 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have made estimates for Aurora Cannabis’ earnings, with the lowest sales estimate coming in at $44.05 million and the highest estimate coming in at $51.35 million. Aurora Cannabis posted sales of $51.93 million during the same quarter last year, which suggests a negative year over year growth rate of 9.3%. The firm is scheduled to announce its next earnings report on Thursday, February 10th.
On average, analysts expect that Aurora Cannabis will report full year sales of $191.19 million for the current year, with estimates ranging from $184.05 million to $199.30 million. For the next fiscal year, analysts forecast that the firm will report sales of $225.28 million, with estimates ranging from $220.35 million to $231.90 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that follow Aurora Cannabis.
Aurora Cannabis (NYSE:ACB) last released its quarterly earnings data on Tuesday, November 9th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.09. Aurora Cannabis had a negative return on equity of 9.09% and a negative net margin of 252.40%. The business had revenue of $47.74 million for the quarter, compared to the consensus estimate of $47.84 million.
Several research firms have recently weighed in on ACB. Needham & Company LLC reissued a “sell” rating on shares of Aurora Cannabis in a research report on Tuesday, September 28th. CIBC raised Aurora Cannabis from an “underperform” rating to a “neutral” rating in a research report on Wednesday, November 10th. MKM Partners raised Aurora Cannabis from a “sell” rating to a “neutral” rating and boosted their target price for the company from $6.00 to $7.00 in a research report on Tuesday, September 28th. Jefferies Financial Group reissued a “hold” rating on shares of Aurora Cannabis in a research report on Friday, October 1st. Finally, Zacks Investment Research raised Aurora Cannabis from a “sell” rating to a “hold” rating in a research report on Thursday, September 30th. Four research analysts have rated the stock with a sell rating and eight have issued a hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $7.08.
NYSE:ACB opened at $5.41 on Monday. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.42 and a quick ratio of 4.13. Aurora Cannabis has a 1 year low of $5.39 and a 1 year high of $18.98. The stock’s 50 day simple moving average is $6.56 and its two-hundred day simple moving average is $7.08. The company has a market cap of $1.07 billion, a price-to-earnings ratio of -2.07 and a beta of 2.99.
Several hedge funds have recently modified their holdings of ACB. Alberta Investment Management Corp lifted its holdings in shares of Aurora Cannabis by 543.9% in the 2nd quarter. Alberta Investment Management Corp now owns 593,700 shares of the company’s stock worth $5,370,000 after buying an additional 501,500 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Aurora Cannabis by 6.2% in the 2nd quarter. Vanguard Group Inc. now owns 5,846,785 shares of the company’s stock worth $52,855,000 after buying an additional 339,238 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of Aurora Cannabis by 482.1% during the 3rd quarter. Dimensional Fund Advisors LP now owns 374,877 shares of the company’s stock worth $2,594,000 after purchasing an additional 310,478 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Aurora Cannabis by 516.1% during the 2nd quarter. Geode Capital Management LLC now owns 293,165 shares of the company’s stock worth $2,651,000 after purchasing an additional 245,578 shares during the last quarter. Finally, U.S. Capital Wealth Advisors LLC purchased a new stake in shares of Aurora Cannabis during the 3rd quarter worth $1,115,000. Institutional investors and hedge funds own 17.17% of the company’s stock.
Aurora Cannabis Company Profile
Aurora Cannabis, Inc engages in the production, distribution and sale of cannabis products. It also produces and sells indoor cultivation systems and hemp related food products. The company was founded by Terry Booth and Steve Dobler on December 21, 2006 and is headquartered in Edmonton, Canada.
Featured Story: What is a death cross?
Get a free copy of the Zacks research report on Aurora Cannabis (ACB)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Want More Great Investing Ideas?
Recent Comments